entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 01:50:54 - browse：49923

What does it mean to a bad CEO? Can biotech endure another election year? And can you go to too many J.P. Morgan parties?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.

For more on what we cover, here are the year’s best CEOs; here are the worst; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Virginia high school admissions case could be legal follow
Next article： Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

WSS

Pfizer plans to depart BIO

What causes an itch? Researchers may have solved the mystery

Congenital heart disease patients face new threat of heart failure

Pregnancy discrimination could be enabled by AI

FDA panel endorses Alnylam’s heart drug — after picking it apart

Telehealth for opioid use disorder is lifesaving

knowledge

entertainment

focus

Dobbs anniversary: the lost opportunity of abortion as health care

In diabetes hearing, Sanders takes on a new foe: food makers

Alkermes shareholders re

Radiology is caught between AI's potential and concern for patients

Novavax promises a turnaround & Lilly roils the obesity market

After sickle

ChatGPT in medicine: STAT answers readers' burning questions

WATCH: Why do bright lights make us see spots?

Medical leaders decry Supreme Court decision on affirmative action

Patients' immediate access to test results puts radiologists in a bind

focus

Patients' immediate access to test results puts radiologists in a bind

How to make the FDA’s new prescription one

Food makers to regulators: Ultra

FDA approves world's first CRISPR

Regeneron agrees to White House price limits on anti

How to make the FDA’s new prescription one

explore

focus

Wikipedia

leisure time